March 20, 2016 |Israeli medical startup DiACardio raised $1.95 million in a post-seed financing round led by China’s Shengjing Group. Other investors in the round include CE Ventures and AltaIR as well as existing backers Agate-Mac Fund and Capital Point Ltd. Based in Beersheva, DiACardio offers software that automates the process of evaluating ultrasounds of the heart, also known as echocardiograms. Based on a new image processing method the company invented, unique and innovative algorithms evaluate the function of the heart fast, accurately and automatically. The software is FDA & CE approved. The Company won 1st place at the Shengjing Global Innovation Awards 2015 and 1st place at the ICI Awards 2015 for innovation in Cardiology. This investment will enable the Company to expand its automated toolbox to other areas of the heart that need automation and expand their business in the US, Europe and the emerging markets. The Company, which started as an incubator company in 2010, was formed by 5 founders: Arnon Toussia-Cohen, Hila Goldman-Aslan, Michal Yaacobi, Dr. Noah Liel-Cohen M.D.,and Prof. Hugo Guterman.
Facebook comments